Amber Salzman
Chief Executive Officer at Epicrispr Biotechnologies, Inc.
Profile
Amber Salzman is the founder of Annapurna Therapeutics SAS, which was founded in 2012.
She held the position of President & Chief Executive Officer from 2012 to 2016.
Currently, she is the President, Chief Executive Officer & Director at Ohana Biosciences, Inc., the Chief Executive Officer at Epicrispr Biotechnologies, Inc., the Director at Drexel University School of Public Health, the Director at Ald Connect, Inc., the Non-Executive Director at AviadoBio Ltd., and the Trustee at Lankenau Institute for Medical Research.
She is also the President of The Stop ALD Foundation since 2001.
In the past, she held the position of President & Chief Executive Officer at CardioKine, Inc. from 2009 to 2011, President, Chief Executive Officer & Director at Adverum Biotechnologies, Inc. from 2016 to 2018, and was a Director at Akcea Therapeutics, Inc. in 2020.
She was also a Member-Research & Development Executive Team at GSK Plc.
Dr. Salzman holds a doctorate degree from Bryn Mawr College and an undergraduate degree from Temple University (Pennsylvania).
Amber Salzman active positions
Companies | Position | Start |
---|---|---|
The Stop ALD Foundation
The Stop ALD Foundation Miscellaneous Commercial ServicesCommercial Services The Stop ALD Foundation is a non-profit organization based in Houston that focuses on accelerating the process of developing new knowledge and new therapies for adrenoleukodystrophy (ALD). ALD is a deadly genetic disease that affects 1 in 18,000 people, most severely affecting boys and men. This brain disorder destroys myelin, the protective sheath that surrounds the brain's neurons, and it knows no racial, ethnic, or geographic barriers. The foundation's mission is to develop therapies for ALD and raise awareness about the disease. | President | 2001-02-28 |
Drexel University School of Public Health | Director/Board Member | - |
Ald Connect, Inc.
Ald Connect, Inc. Services to the Health IndustryHealth Services Ald Connect, Inc. is a non-profit organization that aims to improve health outcomes for patients with adrenoleukodystrophy (ALD) by empowering patients, raising awareness, and accelerating the translation of scientific advances into better clinical care. The non-profit company is based in Middleton, MA, USA. ALD is a rare genetic disease that affects the adrenal glands, the spinal cord, and the white matter of the nervous system. Ald Connect offers various opportunities to get involved with their community, including advocacy, fundraising, volunteering, and participating in their programs or events. | Director/Board Member | - |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | Chief Executive Officer | 2018-06-30 |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | Director/Board Member | - |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Director/Board Member | - |
Epicrispr Biotechnologies, Inc.
Epicrispr Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman. | Chief Executive Officer | - |
Former positions of Amber Salzman
Companies | Position | End |
---|---|---|
AKCEA THERAPEUTICS, INC. | Director/Board Member | 2020-10-11 |
ADVERUM BIOTECHNOLOGIES, INC. | Chief Executive Officer | 2018-05-02 |
░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Amber Salzman
Bryn Mawr College | Doctorate Degree |
Temple University (Pennsylvania) | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
GSK PLC | Health Technology |
ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
Private companies | 9 |
---|---|
CardioKine, Inc.
CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Lankenau Institute for Medical Research
Lankenau Institute for Medical Research BiotechnologyHealth Technology Lankenau Institute for Medical Research operates as a non-profit biomedical research centre. It provides human health and well being through technology development and the training to the next generation of scientists and physicians. The company was founded in 1917 and is headquartered Wynnewood, PA. | Health Technology |
Annapurna Therapeutics SAS
Annapurna Therapeutics SAS BiotechnologyHealth Technology Annapurna Therapeutics SAS operates as a gene therapy company. Its therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. The company was founded by Pierre Bougneres, Hélène Puccio, Amber Salzman, Patrick Aubourg and Ronald G. Crystal and is headquartered in Paris, France. | Health Technology |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
The Stop ALD Foundation
The Stop ALD Foundation Miscellaneous Commercial ServicesCommercial Services The Stop ALD Foundation is a non-profit organization based in Houston that focuses on accelerating the process of developing new knowledge and new therapies for adrenoleukodystrophy (ALD). ALD is a deadly genetic disease that affects 1 in 18,000 people, most severely affecting boys and men. This brain disorder destroys myelin, the protective sheath that surrounds the brain's neurons, and it knows no racial, ethnic, or geographic barriers. The foundation's mission is to develop therapies for ALD and raise awareness about the disease. | Commercial Services |
Ald Connect, Inc.
Ald Connect, Inc. Services to the Health IndustryHealth Services Ald Connect, Inc. is a non-profit organization that aims to improve health outcomes for patients with adrenoleukodystrophy (ALD) by empowering patients, raising awareness, and accelerating the translation of scientific advances into better clinical care. The non-profit company is based in Middleton, MA, USA. ALD is a rare genetic disease that affects the adrenal glands, the spinal cord, and the white matter of the nervous system. Ald Connect offers various opportunities to get involved with their community, including advocacy, fundraising, volunteering, and participating in their programs or events. | Health Services |
Ohana Biosciences, Inc.
Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | Commercial Services |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Health Technology |
Epicrispr Biotechnologies, Inc.
Epicrispr Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Epicrispr Biotechnologies, Inc. is a leading epigenetic editing company based in South San Francisco, CA. The company leverages the power of CRISPR without cutting DNA through its proprietary Gene Expression Modulation System (GEMS), which includes the smallest Cas protein known to work in human cells. Epic's lead program is in IND-enabling studies for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and additional programs seek to address alpha-1 antitrypsin deficiency (A1AD), heterozygous familial hypercholesterolemia (HeFH), and other indications. The company is financially backed by Horizons Ventures and other leading investors. The company was founded by Lei Stanley Qi, and the CEO is Amber Salzman. | Commercial Services |
- Stock Market
- Insiders
- Amber Salzman